Background to Biotome
Biotome, founded in 2017 by Professor Samuel Lundin, Dr Alma Fulurija and Nobel Laureate Professor Barry Marshall, isdeveloping next-generation antibody tests(serology tests) based onprecision immunology.
Their diagnostics involve small pieces of proteins (i.e. peptides) instead of whole proteins as analysis markers. This is a fundamental advantage compared to conventional serology, as it allows the full use of the high resolution of the immune system, resulting inhigher precision and lower cost compared to conventional techniques. An added advantage is that the markers of Biotome’s tests arepatentable, unlike conventional protein markers.
Biotome has three diagnostic projects in the pipeline, each addressing large markets. The most progressed project,HelitopeTM, is a simpleblood test for stomach cancer risk. The two other projects are focused on developing an antibody-test for COVID-19 (CovitopeTM) as well as a test for the risk of pre-eclampsia development.
Register Interest
Biotome has a strong global network of partners and collaborators in industry, academia and the health care sector.
Partnership with BrainChip Ltd in a Project Funded by the Government of Western Australia
BrainChip is a global technology company that is producing a groundbreaking AkidaTMneuromorphic processor chip that brings artificial intelligence to the edge in a way that is beyond the capabilities of other products. In a joint government funded COVID-19 project Biotome will use AkidaTMto identify the antibodies that can protect against SARS- CoV-2 infection – the so-called neutralising antibodies. This could pave the way for a test that determines which level of protection against COVID-19 a person has after having received COVID-19 vaccination or after having been infected with SARS-CoV-2.
Dr. Samuel Lundin, CEO of Biotome on the BrainChip partnership:
“We believe the precision of antibody tests for infections can be improved dramatically. Our partnership with Brainchip is an important step for our development of point-of-care tests that are based on patented high-precision immunological markers. We are very excited to explore how the cutting-edge Akida neural processor can improve the accuracy and information quality of the antibody-tests we are developing, by providing advanced AI capacity at the point of care. If the project is successful we will apply the same principles to other antibody tests in our pipeline.”
Linking Biology up to Computers with Cardea Bio Inc
Biotome engages with partner companies across the globe that can provide point-of-care diagnostic platforms that can be adapted to work with our patented peptide markers. Recently, a technology partnership has been entered with Cardea Bio Inc., a US-based global leader in nanoelectronics manufacturing and the only mass-producer of graphene-based biological transistors. Through joining Cardea’s Innovation Partnership Program, Biotome will leverage Cardea’s graphene field effect transistors to connect biology with modern electronics for high-precision immunology diagnostics, to address the unparalleled global demand for rapid, accurate diagnostic tests.
Graphene-based Cardean TransistorsTMfor precision immunology diagnostics
Current Capital Raising Round
Biotome is currently raising capital to cover costs for progressing the three ongoing projects. This round has so far raised $380k from existing and new investors, and the round will close in Q3 2021. For more information, contact CEO Dr Samuel Lundin – [email protected].
About Biotome Pty Ltd
Biotome is at the forefront of next-generation serology research, which has the potential to drastically improve the performance of diagnostics, ushering in the new era of precision immunology. Using our technology, we discover patentable immunological markers of superior accuracy across a range of diseases. Through strategic partnerships, Biotome integrates linear epitopes with cutting-edge diagnostic assay platforms to access the intrinsic high resolution of the immune system, addressing unmet needs through the development of precision immunology diagnostics.
mid year conclusion too.
(20min delay)